2/11
04:14 pm
gild
Gilead Sciences (NASDAQ:GILD) was given a new $162.00 price target on by analysts at Bank of America Corporation. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) was given a new $162.00 price target on by analysts at Bank of America Corporation. They now have a "buy" rating on the stock.
2/11
12:19 pm
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Royal Bank Of Canada from $103.00 to $118.00. They now have a "sector perform" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Royal Bank Of Canada from $103.00 to $118.00. They now have a "sector perform" rating on the stock.
2/11
12:10 pm
gild
Gilead Sciences (NASDAQ:GILD) was given a new $162.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Gilead Sciences (NASDAQ:GILD) was given a new $162.00 price target on by analysts at Truist Financial Corporation.
2/11
11:58 am
gild
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says [Yahoo! Finance]
Low
Report
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says [Yahoo! Finance]
2/11
11:48 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Truist Financial Corporation from $145.00 to $152.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Truist Financial Corporation from $145.00 to $152.00. They now have a "buy" rating on the stock.
2/11
10:59 am
gild
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
2/11
09:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $150.00 to $165.00. They now have an "overweight" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $150.00 to $165.00. They now have an "overweight" rating on the stock.
2/11
09:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $150.00 to $160.00. They now have an "overweight" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $150.00 to $160.00. They now have an "overweight" rating on the stock.
2/11
09:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $150.00 to $171.00. They now have an "overweight" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $150.00 to $171.00. They now have an "overweight" rating on the stock.
2/11
08:46 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Cantor Fitzgerald from $135.00 to $155.00. They now have an "overweight" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Cantor Fitzgerald from $135.00 to $155.00. They now have an "overweight" rating on the stock.
2/11
08:42 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Scotiabank from $140.00 to $177.00. They now have a "sector outperform" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Scotiabank from $140.00 to $177.00. They now have a "sector outperform" rating on the stock.
2/11
08:00 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Needham & Company LLC from $140.00 to $170.00. They now have a "buy" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Needham & Company LLC from $140.00 to $170.00. They now have a "buy" rating on the stock.
2/11
02:06 am
gild
Gilead Sciences declares $0.82 dividend [Seeking Alpha]
Medium
Report
Gilead Sciences declares $0.82 dividend [Seeking Alpha]
2/10
06:24 pm
gild
Gilead Sciences Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Gilead Sciences Q4 Earnings Call Highlights [Yahoo! Finance]
2/10
05:16 pm
gild
Gilead in charts: Revenue from liver disease product sees highest Y/Y rise of 17% [Seeking Alpha]
Medium
Report
Gilead in charts: Revenue from liver disease product sees highest Y/Y rise of 17% [Seeking Alpha]
2/10
04:26 pm
gild
Gilead Sciences's (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates [Yahoo! Finance]
High
Report
Gilead Sciences's (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates [Yahoo! Finance]
2/10
04:02 pm
gild
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
Medium
Report
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
2/10
04:01 pm
gild
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
2/7
04:17 pm
gild
Assessing Gilead Sciences (GILD) Valuation After Its Strong Recent Share Price Performance [Yahoo! Finance]
Low
Report
Assessing Gilead Sciences (GILD) Valuation After Its Strong Recent Share Price Performance [Yahoo! Finance]
2/6
07:12 pm
gild
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement? [Yahoo! Finance]
Low
Report
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement? [Yahoo! Finance]
2/6
08:30 am
gild
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
Low
Report
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
2/5
01:28 pm
gild
Is Gilead Sciences (GILD) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Low
Report
Is Gilead Sciences (GILD) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
2/4
03:07 pm
gild
GSK's oncology and HIV drugs drive 7% sales rise in 2025 [Yahoo! Finance]
Low
Report
GSK's oncology and HIV drugs drive 7% sales rise in 2025 [Yahoo! Finance]
2/2
07:41 pm
gild
Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]
Low
Report
Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]
2/1
12:59 pm
gild
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]
Low
Report
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]